Compare FWRD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | EDIT |
|---|---|---|
| Founded | 1981 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.3M | 432.8M |
| IPO Year | 2024 | 2016 |
| Metric | FWRD | EDIT |
|---|---|---|
| Price | $18.87 | $2.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $37.50 | $5.30 |
| AVG Volume (30 Days) | 748.8K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.54 | 37.50 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,269,573,000.00 | $31,937,000.00 |
| Revenue This Year | $6.57 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $7.86 | $1.66 |
| 52 Week High | $32.00 | $4.54 |
| Indicator | FWRD | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 71.36 | 48.61 |
| Support Level | $17.41 | $2.77 |
| Resistance Level | $23.55 | $3.27 |
| Average True Range (ATR) | 0.99 | 0.15 |
| MACD | 0.44 | 0.02 |
| Stochastic Oscillator | 81.95 | 48.39 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in North and South America, Europe, and Asia.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.